From Cox some takeaways
Report entitled, Desperate shorter Attackers create Star buying opportunity.
I should clarify that I'm really not that concerned about short-term stock prices, especially in regard to Star Scientific. The potential of anatabine citrate, the active ingredient in Anatabloc, has been validated by the completed thyroiditis study performed by a number of noted endocrinologists from Johns Hopkins Medical School, chiefly the director of endocrinology and metabolism, Dr. Paul W. Ladenson.
The results of this study are simply stunning. Because this is a nutraceutical, however, Star cannot use words like “cure” or “treat.” If they did use that language, the legal status of the compound would then be shifted to “drug” status and would require full regulatory approval. This would be a tragedy for human health, as the actual announced preliminary results of the study are historic, providing the only hope for preventing or reversing thyroiditis and other autoimmune-related diseases.
In other words, all the scientific markers of thyroiditis were decreasing and continuing to improve over time, even at low doses. This is simply astonishing. Nothing has ever produced these results before, and anybody at risk for thyroiditis would be crazy at this point, given two years of toxicity data from Harvard, not to use Anatabloc
The importance of this product, however, is not specific to thyroiditis. We have other human data from the Flint diabetes study that showed a similar effect on adult diabetes. We also have dramatic reductions in C-reactive proteins, a marker for general inflammation, in obese smokers. What this means is that anatabine citrate treats autoimmune disorder, which is complicit in virtually all disease.
So apparently, desperate short attackers have been rattled by the credibility that respected Johns Hopkins scientists have given Star Scientific. They include Dr. Patrizio Caturegli, assistant professor of pathology and endocrinology. You should read,
Your buddy Patrick FOX, is obliged to come out with another insane article to the poor subscribers whose money he took telling them about the up-seen riches they were going to find when he was teasing STSI. The poor chumps, bought when it was at $5- $4-$3-$2- when it hit $1.26 they were scratching their heads wondering what he's gotten'em into while they were watching their equity dissolve before their own eyes.
The newly released article of his is simply to protect his " Derriere" and save face. But he can say all he wants and lie all he wants, VERITAS sooner rather than later will trump any charlatan or legerdemain.
If you and your buddy longs want to take Patrick Fox's word to the bank, I have news for you, whatever you are depositing will bounce like a basketball on Park Avenue.
You should read, by the way, the American Thyroid Association's (ATA) recent praise of Dr. Ladenson when they issued him an official honor. Note, in particular, that the ATA discusses the fact that he is “investigating effects of the nutritional supplement anatabine on autoimmune thyroiditis.”
So the short attackers are now claiming that Star Scientific made up the relationship with Johns Hopkins scientists, despite two publicly announced trials performed under their auspices. That's just bizarre, and I suspect it's solid grounds for legal action if Star wants to commit the resources to defending its reputation.
I speak pretty regularly to these scientists. I have their private phone numbers and have appeared in public with them when they have discussed their results before other scientists. Moreover, I have spoken to those who know what other departments at Hopkins are doing in regard to anatabine citrate.
Johns Hopkins, of course, does not have any “official” involvement with Star Scientific. Johns Hopkins scientists are independent researchers who direct their own work. John Hopkins does issue commercial endorsements, but the organization has no financial stake in the success of Anatabloc. This increases, not decreases, the credibility of the anatabine citrate research results, but the shorters are now using this fact to convince the gullible that there is something inappropriate going on. This level of desperation may mean that there is fear of a short squeeze, which could ruin the shorters.
Who knew you were SO connected?!! You've been laying low in hiding your relationships with the various MDs with regard to anatabine citrate and Abloc.
So I feel the need to ask what kind of MD are you? If not a doctor, what scientific background do you have? I'm very pleased to have you on our side. Either I've been blind (to your posts) or you've been holding out on us!! I look forward to more of your scientific posts in the future.
THANKS for contributing as much as you do.
google a-natabine and Johns Hopkins
Anatabine ameliorates experimental autoimmune thyroiditis.
Caturegli P, De Remigis A, Ferlito M, Landek-Salgado MA, Iwama S, Tzou SC, Ladenson PW.
Department of Pathology, Johns Hopkins University School of Medicine, Ross 656, 720 Rutland Avenue, Baltimore, Maryland 21205, USA. email@example.com